Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New agents for Staphylococcus aureus endocarditis.

Marci Drees1, Helen Boucher

  • 1Tufts-New England Medical Center, Tufts University, Boston, Massachusetts 02111, USA.

Current Opinion in Infectious Diseases
|November 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood Culture Use in Medical and Surgical Intensive Care Units and Wards.

JAMA network open·2025
Same author

Implementing a Successful Influenza and Updated COVID-19 Vaccination Campaign Among Healthcare Workers in a Delaware Healthcare Facility.

Delaware journal of public health·2024
Same author

Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021-August 2022.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2023
Same author

Prevention and Control of Nosocomial Varicella During the United States Varicella Vaccination Program Era.

The Journal of infectious diseases·2022
Same author

Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report.

The Lancet. Infectious diseases·2022
Same author

Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update.

Infection control and hospital epidemiology·2022
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

New agents are needed for Staphylococcus aureus endocarditis due to rising resistance. Daptomycin shows promise as an alternative to vancomycin for methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) infections.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Cardiology

Background:

  • Increasing prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA) necessitates novel treatments.
  • Staphylococcus aureus endocarditis remains a significant clinical challenge.

Purpose of the Study:

  • To review current and emerging antimicrobial agents for treating S. aureus endocarditis.
  • To address the need for effective therapies against resistant S. aureus strains.

Main Methods:

  • Literature review of available and forthcoming antimicrobials.
  • Analysis of clinical outcomes and in vitro activity against S. aureus.

Main Results:

  • Antistaphylococcal penicillins are still preferred for methicillin-sensitive S. aureus (MSSA) endocarditis.

Related Experiment Videos

  • Vancomycin is standard for MRSA but associated with suboptimal outcomes, especially in VISA.
  • Daptomycin demonstrates efficacy and tolerability in MSSA and MRSA bacteremia and right-sided endocarditis.
  • New agents like dalbavancin, telavancin, and ceftobiprole show in vitro activity but lack endocarditis data.

    • Conclusions:

    • Antistaphylococcal penicillins remain the gold standard for MSSA endocarditis.
    • Daptomycin offers a valuable alternative to vancomycin for MRSA/MSSA bacteremia and right-sided endocarditis due to its rapid bactericidal activity.